Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice

Lindsey L. Kennedy, Fanyin Meng, Julie K. Venter, Tianhao Zhou, Walker A. Karstens, Laura A. Hargrove, Nan Wu, Konstantina Kyritsi, John Greene, Pietro Invernizzi, Francesca Bernuzzi, Shannon S. Glaser, Heather L. Francis, Gianfranco Alpini

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Cholestasis is a condition that leads to chronic hepatobiliary inflammation, fibrosis, and eventually cirrhosis. Many microRNAs (miRs) are known to have a role in fibrosis progression; however, the role of miR-21 during cholestasis remains unknown. Therefore, the aim of this study was to elucidate the role of miR-21 during cholestasis-induced biliary hyperplasia and hepatic fibrosis. Wild-type (WT) and miR-21-/- mice underwent Sham or bile duct ligation (BDL) for 1 week, before evaluating liver histology, biliary proliferation, hepatic stellate cell (HSC) activation, fibrotic response, and small mothers against decapentaplegic 7 (Smad-7) expression. In vitro, immortalized murine biliary cell lines (IMCLs) and human hepatic stellate cell line (hHSC) were treated with either miR-21 inhibitor or control before analyzing proliferation, apoptosis, and fibrotic responses. In vivo, the levels of miR-21 were increased in total liver and cholangiocytes after BDL, and loss of miR-21 decreased the amount of BDL-induced biliary proliferation and intrahepatic biliary mass. In addition, loss of miR-21 decreased BDL-induced HSC activation, collagen deposition, and expression of the fibrotic markers transforming growth factor-β1 and α-smooth muscle actin. In vitro, IMCL and hHSCs treated with miR-21 inhibitor displayed decreased proliferation and expression of fibrotic markers and enhanced apoptosis when compared with control treated cells. Furthermore, mice lacking miR-21 show increased Smad-7 expression, which may be driving the decrease in biliary hyperplasia and hepatic fibrosis. During cholestatic injury, miR-21 is increased and leads to increased biliary proliferation and hepatic fibrosis. Local modulation of miR-21 may be a therapeutic option for patients with cholestasis.

Original languageEnglish (US)
Pages (from-to)1256-1267
Number of pages12
JournalLaboratory Investigation
Volume96
Issue number12
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint

Bile Ducts
MicroRNAs
Liver Cirrhosis
Hyperplasia
Fibrosis
Cholestasis
Hepatic Stellate Cells
Ligation
Liver
Cell Line
Mothers
Apoptosis
Transforming Growth Factors
Smooth Muscle
Actins
Histology
Collagen
Inflammation
Wounds and Injuries

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

Kennedy, L. L., Meng, F., Venter, J. K., Zhou, T., Karstens, W. A., Hargrove, L. A., ... Alpini, G. (2016). Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. Laboratory Investigation, 96(12), 1256-1267. https://doi.org/10.1038/labinvest.2016.112

Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. / Kennedy, Lindsey L.; Meng, Fanyin; Venter, Julie K.; Zhou, Tianhao; Karstens, Walker A.; Hargrove, Laura A.; Wu, Nan; Kyritsi, Konstantina; Greene, John; Invernizzi, Pietro; Bernuzzi, Francesca; Glaser, Shannon S.; Francis, Heather L.; Alpini, Gianfranco.

In: Laboratory Investigation, Vol. 96, No. 12, 01.12.2016, p. 1256-1267.

Research output: Contribution to journalArticle

Kennedy, LL, Meng, F, Venter, JK, Zhou, T, Karstens, WA, Hargrove, LA, Wu, N, Kyritsi, K, Greene, J, Invernizzi, P, Bernuzzi, F, Glaser, SS, Francis, HL & Alpini, G 2016, 'Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice', Laboratory Investigation, vol. 96, no. 12, pp. 1256-1267. https://doi.org/10.1038/labinvest.2016.112
Kennedy, Lindsey L. ; Meng, Fanyin ; Venter, Julie K. ; Zhou, Tianhao ; Karstens, Walker A. ; Hargrove, Laura A. ; Wu, Nan ; Kyritsi, Konstantina ; Greene, John ; Invernizzi, Pietro ; Bernuzzi, Francesca ; Glaser, Shannon S. ; Francis, Heather L. ; Alpini, Gianfranco. / Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. In: Laboratory Investigation. 2016 ; Vol. 96, No. 12. pp. 1256-1267.
@article{4174d97918bd48f2bb21c82a10971e15,
title = "Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice",
abstract = "Cholestasis is a condition that leads to chronic hepatobiliary inflammation, fibrosis, and eventually cirrhosis. Many microRNAs (miRs) are known to have a role in fibrosis progression; however, the role of miR-21 during cholestasis remains unknown. Therefore, the aim of this study was to elucidate the role of miR-21 during cholestasis-induced biliary hyperplasia and hepatic fibrosis. Wild-type (WT) and miR-21-/- mice underwent Sham or bile duct ligation (BDL) for 1 week, before evaluating liver histology, biliary proliferation, hepatic stellate cell (HSC) activation, fibrotic response, and small mothers against decapentaplegic 7 (Smad-7) expression. In vitro, immortalized murine biliary cell lines (IMCLs) and human hepatic stellate cell line (hHSC) were treated with either miR-21 inhibitor or control before analyzing proliferation, apoptosis, and fibrotic responses. In vivo, the levels of miR-21 were increased in total liver and cholangiocytes after BDL, and loss of miR-21 decreased the amount of BDL-induced biliary proliferation and intrahepatic biliary mass. In addition, loss of miR-21 decreased BDL-induced HSC activation, collagen deposition, and expression of the fibrotic markers transforming growth factor-β1 and α-smooth muscle actin. In vitro, IMCL and hHSCs treated with miR-21 inhibitor displayed decreased proliferation and expression of fibrotic markers and enhanced apoptosis when compared with control treated cells. Furthermore, mice lacking miR-21 show increased Smad-7 expression, which may be driving the decrease in biliary hyperplasia and hepatic fibrosis. During cholestatic injury, miR-21 is increased and leads to increased biliary proliferation and hepatic fibrosis. Local modulation of miR-21 may be a therapeutic option for patients with cholestasis.",
author = "Kennedy, {Lindsey L.} and Fanyin Meng and Venter, {Julie K.} and Tianhao Zhou and Karstens, {Walker A.} and Hargrove, {Laura A.} and Nan Wu and Konstantina Kyritsi and John Greene and Pietro Invernizzi and Francesca Bernuzzi and Glaser, {Shannon S.} and Francis, {Heather L.} and Gianfranco Alpini",
year = "2016",
month = "12",
day = "1",
doi = "10.1038/labinvest.2016.112",
language = "English (US)",
volume = "96",
pages = "1256--1267",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice

AU - Kennedy, Lindsey L.

AU - Meng, Fanyin

AU - Venter, Julie K.

AU - Zhou, Tianhao

AU - Karstens, Walker A.

AU - Hargrove, Laura A.

AU - Wu, Nan

AU - Kyritsi, Konstantina

AU - Greene, John

AU - Invernizzi, Pietro

AU - Bernuzzi, Francesca

AU - Glaser, Shannon S.

AU - Francis, Heather L.

AU - Alpini, Gianfranco

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Cholestasis is a condition that leads to chronic hepatobiliary inflammation, fibrosis, and eventually cirrhosis. Many microRNAs (miRs) are known to have a role in fibrosis progression; however, the role of miR-21 during cholestasis remains unknown. Therefore, the aim of this study was to elucidate the role of miR-21 during cholestasis-induced biliary hyperplasia and hepatic fibrosis. Wild-type (WT) and miR-21-/- mice underwent Sham or bile duct ligation (BDL) for 1 week, before evaluating liver histology, biliary proliferation, hepatic stellate cell (HSC) activation, fibrotic response, and small mothers against decapentaplegic 7 (Smad-7) expression. In vitro, immortalized murine biliary cell lines (IMCLs) and human hepatic stellate cell line (hHSC) were treated with either miR-21 inhibitor or control before analyzing proliferation, apoptosis, and fibrotic responses. In vivo, the levels of miR-21 were increased in total liver and cholangiocytes after BDL, and loss of miR-21 decreased the amount of BDL-induced biliary proliferation and intrahepatic biliary mass. In addition, loss of miR-21 decreased BDL-induced HSC activation, collagen deposition, and expression of the fibrotic markers transforming growth factor-β1 and α-smooth muscle actin. In vitro, IMCL and hHSCs treated with miR-21 inhibitor displayed decreased proliferation and expression of fibrotic markers and enhanced apoptosis when compared with control treated cells. Furthermore, mice lacking miR-21 show increased Smad-7 expression, which may be driving the decrease in biliary hyperplasia and hepatic fibrosis. During cholestatic injury, miR-21 is increased and leads to increased biliary proliferation and hepatic fibrosis. Local modulation of miR-21 may be a therapeutic option for patients with cholestasis.

AB - Cholestasis is a condition that leads to chronic hepatobiliary inflammation, fibrosis, and eventually cirrhosis. Many microRNAs (miRs) are known to have a role in fibrosis progression; however, the role of miR-21 during cholestasis remains unknown. Therefore, the aim of this study was to elucidate the role of miR-21 during cholestasis-induced biliary hyperplasia and hepatic fibrosis. Wild-type (WT) and miR-21-/- mice underwent Sham or bile duct ligation (BDL) for 1 week, before evaluating liver histology, biliary proliferation, hepatic stellate cell (HSC) activation, fibrotic response, and small mothers against decapentaplegic 7 (Smad-7) expression. In vitro, immortalized murine biliary cell lines (IMCLs) and human hepatic stellate cell line (hHSC) were treated with either miR-21 inhibitor or control before analyzing proliferation, apoptosis, and fibrotic responses. In vivo, the levels of miR-21 were increased in total liver and cholangiocytes after BDL, and loss of miR-21 decreased the amount of BDL-induced biliary proliferation and intrahepatic biliary mass. In addition, loss of miR-21 decreased BDL-induced HSC activation, collagen deposition, and expression of the fibrotic markers transforming growth factor-β1 and α-smooth muscle actin. In vitro, IMCL and hHSCs treated with miR-21 inhibitor displayed decreased proliferation and expression of fibrotic markers and enhanced apoptosis when compared with control treated cells. Furthermore, mice lacking miR-21 show increased Smad-7 expression, which may be driving the decrease in biliary hyperplasia and hepatic fibrosis. During cholestatic injury, miR-21 is increased and leads to increased biliary proliferation and hepatic fibrosis. Local modulation of miR-21 may be a therapeutic option for patients with cholestasis.

UR - http://www.scopus.com/inward/record.url?scp=84996520539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996520539&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2016.112

DO - 10.1038/labinvest.2016.112

M3 - Article

C2 - 27775690

AN - SCOPUS:84996520539

VL - 96

SP - 1256

EP - 1267

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 12

ER -